Journal of Antimicrobial Chemotherapy (2001) 48, 209-217
© 2001 The British Society for Antimicrobial Chemotherapy
In vitro activity of fosfomycin in combination with various antistaphylococcal substances
Institute for Hygiene and Social Medicine, University of Innsbruck, Fritz Pregl-Strasse 3, A-6020 Innsbruck, Austria
Using the chequerboard technique we studied the in vitro activity of the broad spectrum antibiotic fosfomycin in combination with vancomycin, rifampicin, linezolid, quinupristin/ dalfopristin, cefazolin, meropenem and moxifloxacin against two Staphylococcus epidermidis strains (ATCC 12228, DSM 3269) and five Staphylococcus aureus isolates (ATCC 29213, DSM 683, DSM 46320, GISA 323/93, MRSA 3558/00). The phenomena of ‘trailing’ and ‘skipped wells’ did not present a problem. Synergy was the most common effect of all drugs tested in combination with fosfomycin; only combination with vancomycin showed antagonism for two of seven isolates. Using a killing-curve technique fosfomycin showed cidal activity, where increasing the drug concentration above the MIC did not enhance killing velocity. Inhibitory concentrations of vancomycin plus fosfomycin against DSM 46320 caused effects identical to those observed with vancomycin alone. The combination of fosfomycin plus linezolid exerted the bacteriostatic effect found with linezolid alone. Fosfomycin plus quinupristin/dalfopristin exhibited the bactericidal effect found with fosfomycin alone (in contrast to the rapidly bactericidal effect of quinupristin/dalfopristin). Electron microscopy showed that fosfomycin given in combination with linezolid, quinupristin/dalfopristin or moxifloxacin (substances that do not cause morphological alterations when given alone) resulted in ‘cauliflower-shaped’ distortion as caused by fosfomycin alone. Our in vitro data indicate considerable potential for fosfomycin used in combination with other antistaphylococcal antimicrobials, especially linezolid or quinupristin/dalfopristin.
* Corresponding author. Tel: +43-512-583391; Fax: +43-512-574414; E-mail: Franz.Allerberger{at}uibk.ac.at
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Sauermann, R. Schwameis, M. Fille, M. L. Camuz Ligios, and M. Zeitlinger Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro J. Antimicrob. Chemother., October 1, 2009; 64(4): 821 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. MacLeod, L. M. Barker, J. L. Sutherland, S. C. Moss, J. L. Gurgel, T. F. Kenney, J. L. Burns, and W. R. Baker Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis J. Antimicrob. Chemother., October 1, 2009; 64(4): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Schintler, F. Traunmuller, J. Metzler, G. Kreuzwirt, S. Spendel, O. Mauric, M. Popovic, E. Scharnagl, and C. Joukhadar High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection J. Antimicrob. Chemother., September 1, 2009; 64(3): 574 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukata, N. Imai, and S. Shibata Acute renal insufficiency in cats after fosfomycin administration Vet Rec., September 13, 2008; 163(11): 337 - 338. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Perlroth, M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature Arch Intern Med, April 28, 2008; 168(8): 805 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gattringer, B. Meyer, G. Heinz, C. Guttmann, M. Zeitlinger, C. Joukhadar, P. Dittrich, and F. Thalhammer Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration J. Antimicrob. Chemother., August 1, 2006; 58(2): 367 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sauermann, R. Karch, H. Langenberger, J. Kettenbach, B. Mayer-Helm, M. Petsch, C. Wagner, T. Sautner, R. Gattringer, G. Karanikas, et al. Antibiotic Abscess Penetration: Fosfomycin Levels Measured in Pus and Simulated Concentration-Time Profiles Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4448 - 4454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Beharry and T. Palzkill Functional Analysis of Active Site Residues of the Fosfomycin Resistance Enzyme FosA from Pseudomonas aeruginosa J. Biol. Chem., May 6, 2005; 280(18): 17786 - 17791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jacqueline, D. Navas, E. Batard, A.-F. Miegeville, V. Le Mabecque, M.-F. Kergueris, D. Bugnon, G. Potel, and J. Caillon In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., January 1, 2005; 49(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pfausler, H. Spiss, P. Dittrich, M. Zeitlinger, E. Schmutzhard, and C. Joukhadar Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis J. Antimicrob. Chemother., May 1, 2004; 53(5): 848 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Brown and B. B Freeman III Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections Ann. Pharmacother., April 1, 2004; 38(4): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Pag, M. Oedenkoven, N. Papo, Z. Oren, Y. Shai, and H.-G. Sahl In vitro activity and mode of action of diastereomeric antimicrobial peptides against bacterial clinical isolates J. Antimicrob. Chemother., February 1, 2004; 53(2): 230 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Joukhadar, N. Klein, P. Dittrich, M. Zeitlinger, A. Geppert, K. Skhirtladze, M. Frossard, G. Heinz, and M. Muller Target site penetration of fosfomycin in critically ill patients J. Antimicrob. Chemother., May 1, 2003; 51(5): 1247 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jacqueline, J. Caillon, V. Le Mabecque, A.-F. Miegeville, P.-Y. Donnio, D. Bugnon, and G. Potel In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods J. Antimicrob. Chemother., April 1, 2003; 51(4): 857 - 864. [Abstract] [Full Text] [PDF]
|
|